Compounded Semaglutide: Guide to Prescription, Dosing, Cost, Risks and Legality (2026)

Key takeaways

• Compounded semaglutide is the same molecule as Ozempic and Wegovy mixed by a pharmacy into a multi-dose vial. FDA never reviews the compounded product, so its potency, purity and sterility rest on the pharmacy alone.
• Everything we know about what semaglutide does comes from the brand trials: about 15% weight loss at 68 weeks in adults without diabetes, about 10% in type 2 diabetes, and 20% fewer heart attacks, strokes and cardiovascular deaths in people with heart disease. The compounded product has no trials of its own.
• The dose that was studied is the Wegovy schedule: 0.25 mg weekly, stepped up every four weeks to 2.4 mg. In a 2.5 mg/mL vial, 0.25 mg is 10 units on an insulin syringe and 2.4 mg is 96 units. Getting that arithmetic wrong is the risk that belongs to vials, not pens.
• In October 2026 compounded semaglutide costs $150 to $350 a month; Wegovy costs $349 through the manufacturer, $199 for the first two months for new patients, and the Wegovy pill starts at $149. At low doses the price gap has nearly closed.
• Legally, the shortage that allowed mass compounding ended on February 21, 2025. A pharmacy may now compound semaglutide only for a patient with a documented clinical need the approved products cannot meet. FDA sent 55 warning letters to telehealth companies in 2026 over how compounded GLP-1s were marketed.

Semaglutide (compounded) at a glance

Also called

compounded semaglutide, compound semaglutide, semaglutide vial, semaglutide/cyanocobalamin, semaglutide with B12

Class

Glucagon-like peptide-1 (GLP-1) receptor agonist; a 31-amino-acid analog of human GLP-1 with a fatty-acid side chain that extends its half-life to about one week

Route

Subcutaneous injection once weekly, drawn from a multi-dose vial with an insulin syringe (the brands use fixed-dose pens; Wegovy also comes as a once-daily tablet)

FDA status

Semaglutide itself is FDA-approved as Ozempic (type 2 diabetes), Wegovy injection and Wegovy tablets (weight management and cardiovascular risk reduction) and Rybelsus. Compounded semaglutide is an unapproved copy prepared by a pharmacy: FDA does not review its safety, potency or sterility, and since the shortage was declared resolved on February 21, 2025 it may be compounded only for a patient with a documented clinical need the approved products cannot meet.

FDA Category 2 (compounding restricted)

No

Available by prescription (US)

Brand Wegovy and Ozempic by prescription; compounded only for a documented individual clinical need

Best-studied use

The brand trials: chronic weight management (STEP 1, 2, 4 and 5), type 2 diabetes (SUSTAIN-6) and cardiovascular risk reduction (SELECT). No randomized trial of the compounded product exists.

Typical monthly cost (telehealth, 2026)

$150 to $350 a month through telehealth in October 2026, against $349 for Wegovy through the manufacturer program ($199 for the first two months for new patients)

What compounded semaglutide is, and what it is not

Semaglutide is a synthetic analog of GLP-1, the gut hormone that signals fullness after a meal: it slows stomach emptying, blunts appetite and raises insulin release when glucose is high. Two modifications (an amino acid swap that resists breakdown and a fatty-acid chain that binds albumin) give it a half-life of about a week, which is why one injection lasts seven days (Wegovy label).

Four approved products contain it, all made by Novo Nordisk: Ozempic, a weekly injection for type 2 diabetes in multi-dose pens that dial 0.25, 0.5, 1 or 2 mg; Wegovy injection, single-dose pens of 0.25 to 2.4 mg (plus a 7.2 mg strength and a multi-dose FlexTouch pen since 2026) approved for chronic weight management, cardiovascular risk reduction in adults with heart disease and obesity, and MASH liver disease; Wegovy tablets, a once-daily pill approved in December 2025 that steps up to 25 mg; and Rybelsus, the older daily tablet for type 2 diabetes.

Compounded semaglutide is none of these. A compounding pharmacy buys semaglutide as a bulk powder, dissolves it in sterile water with a preservative, and fills it into a vial at a concentration it chooses, usually 2.5 mg/mL or 5 mg/mL; you draw each dose with an insulin syringe. Some pharmacies add cyanocobalamin (vitamin B12), glycine or other ingredients, and some sell sublingual drops or dissolving tablets, none of which has been tested (Belcourt 2026).

Two kinds of pharmacy can compound it. A 503A pharmacy is licensed by the state and prepares medication for one named patient on a prescription; FDA does not inspect its products. A 503B outsourcing facility registers with FDA, makes batches and is inspected, but may only use ingredients on FDA's clinical-need list or in shortage; in May 2026 FDA proposed to keep semaglutide off that list (Federal Register, May 1, 2026), so compounded semaglutide in 2026 is almost entirely a 503A product.

The difference from a brand pen to hold onto: no regulator checks what is in the vial. The pharmacy's own testing, if any, is the only quality control, and the dose depends on you reading a syringe correctly.

The salt-form problem

Semaglutide in the approved drugs is the base peptide. Early in the shortage, some compounders bought semaglutide sodium or semaglutide acetate, salt forms sold by chemical suppliers that are cheaper and easier to source. In a letter to the National Association of Boards of Pharmacy on April 27, 2023, and in a public statement the following month, FDA said the salts are different active ingredients from the base form in the approved products, that they have not been shown to be safe or effective, and that it was "not aware of any basis for compounding" with them that would meet federal requirements; the shortage listing, FDA added, did not authorize compounding salt forms (FDA GLP-1 page). North Carolina, West Virginia and Mississippi pharmacy boards banned the salts outright, and the compounding lawyers at McGuireWoods warned pharmacies that FDA and the manufacturer could both act against those using them (McGuireWoods 2023).

For a patient the point is simple: a legitimate label says "semaglutide," not "semaglutide sodium" or "semaglutide acetate," and the pharmacy can show a certificate of analysis for the base ingredient from an FDA-registered supplier.

Who can prescribe it, and what a legitimate label looks like

Any clinician with prescribing authority in your state (physician, nurse practitioner or physician assistant, depending on state law) can prescribe semaglutide, brand or compounded, after a legitimate evaluation; telehealth is fine if the prescriber is licensed where you are at the time of the visit. For a compounded version the prescriber must also document why the approved product will not work for you, because since the shortage ended that documentation is what makes the prescription legal rather than a copy.

A pharmacy label written by people who expect you to measure a dose carries your name, the prescriber's name and the pharmacy's name, address and phone number; the drug named as semaglutide with its concentration (for example 2.5 mg/mL) and total volume; the dose in milligrams and in the matching volume or syringe units (0.25 mg = 0.1 mL = 10 units); a beyond-use date, storage instructions and a lot number; and the syringe size that fits the dose. FDA's July 2024 alert on dosing errors asked prescribers and pharmacies for exactly this: match the syringe to the dose, write the dose so it cannot be misread, and show the patient how to draw it (FDA dosing-error alert 2024). A vial that arrives with a bag of syringes and a video link is a product, not a prescription service.

What the evidence actually shows

The semaglutide evidence base is one of the largest for any drug of the last decade, and all of it was generated with the brand product. We grade the claims a compounded program borrows from it, then the claims that belong to the compounded product itself.

Semaglutide claims, graded by the evidence behind them (brand trials unless stated)

Claim	Grade	What the evidence shows	Sources
Large weight loss in adults with obesity and no diabetes	A	STEP 1: 1,961 adults with BMI 30 or more (27 with a weight-related condition), 2.4 mg weekly for 68 weeks plus lifestyle advice. Weight change -14.9% versus -2.4% on placebo (-15.3 kg versus -2.6 kg); 86% lost at least 5%, half lost at least 15%.	Wilding 2021
Weight loss in type 2 diabetes	A	STEP 2: 1,210 adults with type 2 diabetes and BMI 27 or more, 68 weeks. Weight change -9.6% on 2.4 mg versus -3.4% on placebo; 69% versus 29% lost at least 5%. Smaller than in people without diabetes, as with every obesity drug.	Davies 2021
Fewer heart attacks, strokes and cardiovascular deaths	A	SELECT: 17,604 adults with existing cardiovascular disease and BMI 27 or more, no diabetes, mean follow-up 3.3 years. Major cardiovascular events 6.5% on 2.4 mg versus 8.0% on placebo (hazard ratio 0.80). SUSTAIN-6 found the same direction in 3,297 people with type 2 diabetes (6.6% versus 8.9%).	Lincoff 2023; Marso 2016
Weight loss holds while you keep taking it	A	STEP 5: 304 adults, 104 weeks. Weight change -15.2% versus -2.6%; 77% versus 34% kept at least 5% off at two years.	Garvey 2022
Weight returns after you stop	A	STEP 4: after a 20-week run-in in which 803 adults lost 10.6%, those who continued 2.4 mg lost a further 7.9% over 48 weeks; those switched to placebo regained 6.9%, about two thirds of what they had lost.	Rubino 2021
The Wegovy pill does what the injection does	B	OASIS 4: 307 adults, oral semaglutide 25 mg daily for 64 weeks. Weight change -13.6% versus -2.2%; gastrointestinal events in 74% versus 42%. No head-to-head trial against the 2.4 mg injection.	Wharton 2025
Compounded vials produce the same results as the brand	D	No randomized or comparative trial. The only published outcome data are a retrospective series of 94 clients of a wellness studio on compounded semaglutide/B12, who lost 4.6% in three months with no control group and no potency testing. A 2025 survey of compounded products found half contained untested additives and only 18% stated a beyond-use date.	Chun 2025; Belcourt 2026
A vial is as safe to use as a pen	D	The data point the other way: a poison-center series documented 10-fold self-dosing errors from vials dispensed without counseling, and in FDA's adverse-event database reports involving compounded GLP-1s had higher odds of preparation errors, contamination, manufacturing problems and hospitalization than reports involving the approved products.	Lambson 2023; McCall 2026

Three things follow. The headline numbers are real, and a program that says "semaglutide produces about 15% weight loss" is quoting good science. That science used the brand's measured doses, delivered by pens, in people who were screened and monitored, so it transfers to a vial only to the extent that the vial contains what it says and you inject what the schedule says. And nobody has tested the additives: FDA has said that adding an ingredient without a clinical rationale does not create the clinical need that makes a compounded copy legal (FDA GLP-1 page).

What you are promised versus what is documented

Compounded semaglutide versus the alternatives

The compounded semaglutide versus tirzepatide guide covers the head-to-head data (tirzepatide produced more weight loss in its trials and costs more), and the compounded tirzepatide hub covers that product's version of every issue on this page.

Dosing: what the label says and what the syringe shows

The Wegovy label starts at 0.25 mg once a week for four weeks, then 0.5 mg for four weeks, 1 mg for four weeks, 1.7 mg for four weeks, and 2.4 mg from week 17 onward as the recommended maintenance dose (1.7 mg is an accepted alternative). If a step is not tolerated, the label says to delay the next increase by four weeks. Since 2026 the label allows an increase to a maximum of 7.2 mg for adults who have tolerated 2.4 mg for at least four weeks and need more weight reduction (Wegovy label). Ozempic follows the same first two steps and tops out at 2 mg for glucose control (Ozempic label).

A worked units example

Compounded vials are labeled by concentration, and the dose you draw is a volume. On a standard U-100 insulin syringe, 100 units equal 1 mL, so the conversion is units = dose in mg ÷ concentration in mg/mL × 100.

The same "10 units" is 0.25 mg in one vial and 0.5 mg in the other: that is the whole dosing-error problem in one row, and why units mean nothing without the concentration on your label. Run your own numbers in the reconstitution calculator, read how many units are in 1 mL if syringes are new to you, and use the full semaglutide dosage chart for the Ozempic schedule, missed-dose rules and brand pen equivalents. Technique is in how to inject peptides.

What it costs in October 2026

Our peptide therapy cost guide collected these prices on October 9, 2026:

• Compounded semaglutide: $150 to $350 a month month-to-month, $100 to $200 on 3- to 12-month plans, and headline prices of $69 to $99 for the lowest dose on a long commitment. Many programs raise the price as the dose rises.
• Wegovy injection: $349 a month for cash patients through the manufacturer's pharmacy and the federal TrumpRx site, and $199 a month for the first two fills for new patients in 2026. The list price is about $1,350.
• Wegovy tablets: $149 a month at the starting dose, rising to $299 at maintenance doses.
• Ozempic: about $350 a month on TrumpRx, prescribed for type 2 diabetes.

The honest conclusion is that the gap has closed at the bottom of the schedule. For the first two months a new patient pays $199 for Wegovy and $150 to $250 for a compounded program that may bill visits, labs or shipping separately. At maintenance the compounded product is still cheaper, typically by $50 to $200 a month, and that difference buys a product nobody has tested in place of one tested in 20,000 people. If the budget allows the brand, the brand is the better purchase.

The risks that belong to compounded versions

Semaglutide's own side effects are mostly gastrointestinal and are covered, with the label's frequency table, in compounded semaglutide side effects. Four risks come from the compounded format rather than the molecule.

Dosing errors. On July 26, 2024, FDA warned that patients had taken 5 to 20 times the intended dose of compounded semaglutide, some ending up in hospital: a patient told to draw 5 units drew 50; a prescriber wrote 25 units when 5 was intended, another wrote 20 instead of 2 and three patients were left vomiting; a health professional miscalculated her own dose tenfold (FDA dosing-error alert 2024). A poison-center series described two 10-fold self-dosing errors, one by a patient given a vial and syringes with no pharmacist counseling who was thinking in milliliters and units rather than milligrams (Lambson 2023). Pens cannot do this; vials can.

Unverified potency and sterility. No regulator tests a 503A product before it ships. In FDA's adverse-event database, reports involving compounded GLP-1s showed far higher odds of preparation errors, contamination and compounding or manufacturing problems than reports involving the approved products, and higher odds of hospitalization (McCall 2026). Reporting is voluntary and uneven, so these are signals rather than rates, but they point the same direction.

Salt forms and additives. A vial of semaglutide sodium or acetate is a different ingredient, and the B12, glycine and niacinamide in about half of compounded products have never been tested with the drug (Belcourt 2026).

The reporting gap. By May 31, 2026, FDA had received 990 adverse-event reports involving compounded semaglutide and more than 730 involving compounded tirzepatide. A report does not prove causation, and FDA says the totals are probably undercounts because many state-licensed pharmacies are not required to report at all (Drug Discovery and Development 2026).

Who should not take it

The label contraindications and warnings apply to the molecule whoever makes it (Wegovy label):

• a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2 (the boxed warning, based on thyroid tumors in rodents);
• a prior serious allergic reaction to semaglutide;
• pregnancy or planning one (stop at least two months before, because of the long half-life); breastfeeding is unstudied;
• type 1 diabetes, or insulin or sulfonylurea use without a clinician adjusting those doses, because of hypoglycemia;
• a history of pancreatitis or gallbladder disease (label warnings) or severe gastroparesis (not recommended);
• diabetic retinopathy, which needs monitoring because rapid glucose improvement can worsen it temporarily;
• a planned surgery under anesthesia or deep sedation, which the anesthesia team must know about.

Semaglutide is approved for weight management from age 12, but the compounding allowance for a documented individual need applies to a specific patient, not a category; a program selling compounded semaglutide to teenagers or for a few "vanity" pounds has left the evidence and the law behind. Older adults need no dose adjustment, but the label notes that kidney injury from dehydration occurred more often in people with existing kidney impairment and during titration.

Legal status in the United States, October 2026

The facts of record are kept current in our legal tracker; here is how they apply to semaglutide.

• Semaglutide is an approved drug; the question is only about copies. Under section 503A, a pharmacy may compound for an individual patient but not produce what is "essentially a copy" of a commercially available drug, regularly or in inordinate amounts. The exception is a prescriber's documented determination that a change (a different strength or dosage form, or removing an ingredient the patient cannot tolerate) makes a significant difference for that patient.
• The shortage ended. While Ozempic and Wegovy were in shortage (2022 to early 2025), the copy restriction was suspended and pharmacies compounded semaglutide in volume. FDA declared the shortage resolved on February 21, 2025, with grace periods ending April 22, 2025 for 503A pharmacies and May 22, 2025 for 503B facilities (FDA semaglutide order 2025). Since then, price and convenience are not a clinical need, and neither is an added vitamin.
• 2026 enforcement. FDA sent warning letters to 30 telehealth companies on March 3, 2026 and 25 more on June 16, 2026 over marketing that presented compounded GLP-1s as equivalent to, or approved like, the brand products (FDA, March 2026). On May 1, 2026 it proposed to keep semaglutide, tirzepatide and liraglutide off the 503B clinical-need list (Federal Register, May 1, 2026), and on August 24, 2026 it warned five online vendors selling semaglutide and other peptides as "research use only."
• What is legal now. A 503A pharmacy may fill a prescription for a patient whose documented need the approved products cannot meet. A website offering compounded semaglutide to everyone at a discount is doing something else, and FDA has said so in 55 letters. Possession is not the issue: semaglutide is not a controlled substance, and the law acts on sellers and compounders, not patients.

How to tell a legitimate program from a copy-marketing operation

A legitimate program in 2026 looks like a medical practice that uses a compounding pharmacy for a reason. A copy-marketing operation looks like a store.

Our directory of online peptide clinics applies these tests to named providers.

Bottom line

Compounded semaglutide is a real drug in an unregulated package. The molecule has better evidence than almost anything else sold for weight loss: about 15% weight loss in people without diabetes, about 10% with it, and fewer cardiovascular events in people with heart disease, all from trials of the brand at the label doses. What the compounded version adds is risk the brand does not carry: a dose you measure yourself, a potency nobody verifies, salt forms and additives that were never studied, and a legal basis that since February 2025 requires a documented individual need rather than a lower price.

In October 2026 the price argument is weaker than it was: Wegovy at $199 for the first two months and $349 after, and a $149 starting pill, have narrowed the gap to a few hundred dollars a year at low doses. If you can pay for the brand, pay for the brand. If you choose a compounded program, choose one that names its pharmacy and its ingredient, writes your dose in milligrams and units next to the concentration, and treats you as a patient rather than a subscriber.

Frequently asked questions

+−Is compounded semaglutide the same as Ozempic?

The molecule is meant to be the same, but the product is not. Ozempic and Wegovy are manufactured by Novo Nordisk under FDA oversight and dispensed in pens with fixed doses. Compounded semaglutide is mixed by a pharmacy from bulk semaglutide, supplied in a multi-dose vial, and never reviewed by FDA for potency, purity or sterility. Some compounders have also used semaglutide sodium or semaglutide acetate, salt forms that FDA says are different active ingredients from the base semaglutide in the approved drugs. Telling patients a compounded product is the same as Ozempic was one of the claims that drew FDA warning letters in 2026.

+−Is the FDA banning compounded semaglutide?

Not outright, but the window has mostly closed. FDA declared the semaglutide shortage resolved on February 21, 2025, which ended the period when pharmacies could compound copies in volume. A 503A pharmacy may still compound semaglutide for an individual patient whose documented clinical need cannot be met by the approved product, for example a true allergy to an excipient, but not as a cheaper copy. In 2026 FDA sent 55 warning letters to telehealth companies over how compounded GLP-1s were marketed and proposed, on May 1, 2026, to keep semaglutide off the list of substances outsourcing facilities may use.

+−Is compounded semaglutide safe?

The active ingredient has an unusually good safety record in trials of more than 20,000 people, but those trials used the brand product. The risks that belong to compounded versions are different: dosing errors of 5 to 20 times the intended dose when units and milliliters are confused, potency that no regulator tests, salt forms, and added ingredients such as B12 that were never studied with semaglutide. FDA had received 990 adverse-event reports involving compounded semaglutide by May 31, 2026, and says the true number is probably higher.

+−What is in compounded semaglutide?

It should be semaglutide base dissolved in sterile water with a preservative, usually at 2.5 mg/mL or 5 mg/mL. In practice many products add cyanocobalamin (vitamin B12), glycine, niacinamide or other ingredients; a 2025 survey of compounding websites found that about half of the compounded semaglutide and tirzepatide products contained such additives, and only 18% stated a beyond-use date. None of the additives has been shown to improve results or reduce side effects, and FDA has said that adding an ingredient without a clinical rationale does not make a compounded product legal.

+−How much does compounded semaglutide cost?

In October 2026, telehealth programs charge about $150 to $350 a month month-to-month, $100 to $200 on 3- to 12-month plans, and as little as $69 to $99 for the lowest dose on a long commitment. Wegovy costs $349 a month for cash patients through the manufacturer, $199 a month for the first two fills for new patients in 2026, and the Wegovy pill starts at $149. At the starting doses the gap between a compounded program and the brand is now small or zero.

+−What happens if you stop taking semaglutide?

Appetite returns within weeks as the drug clears, and most of the weight comes back unless something else changes. In the STEP 4 trial, people who had lost about 10.6% of their weight in 20 weeks on semaglutide lost a further 7.9% over the next 48 weeks if they stayed on it and regained 6.9% if they were switched to placebo. The drug stays in the body for about five to seven weeks after the last dose.

+−What category of drug is semaglutide?

It is a GLP-1 receptor agonist, a prescription-only peptide hormone analog. It is not a controlled substance, not a stimulant and not a hormone in the sense of testosterone or estrogen. Tirzepatide belongs to a related class that also activates the GIP receptor.

+−How long does compounded semaglutide last in the fridge?

Until the beyond-use date printed on the pharmacy label, which is commonly 28 days after the vial is first punctured. Keep it refrigerated at 36 to 46 degrees Fahrenheit and do not freeze it. For comparison, an unopened Wegovy pen may sit at room temperature for up to 28 days, and an opened Ozempic pen is good for 56 days.

+−Is semaglutide a peptide?

Yes. It is a modified version of the human hormone GLP-1, a chain of 31 amino acids with changes that stop enzymes from breaking it down and a fatty-acid chain that binds it to albumin in the blood. That is why one injection lasts a week. It is a peptide drug in the same sense that insulin is.

Sources

1. StudyWilding JPH et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1). N Engl J Med 2021;384:989-1002. (2021)
2. StudyDavies M et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. Lancet 2021;397:971-84. (2021)
3. StudyLincoff AM et al. Semaglutide and cardiovascular outcomes in obesity without diabetes (SELECT). N Engl J Med 2023;389:2221-32. (2023)
4. StudyMarso SP et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes (SUSTAIN-6). N Engl J Med 2016;375:1834-44. (2016)
5. StudyRubino D et al. Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity: the STEP 4 randomized clinical trial. JAMA 2021;325:1414-25. (2021)
6. StudyGarvey WT et al. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nat Med 2022;28:2083-91. (2022)
7. StudyWharton S et al. Oral semaglutide at a dose of 25 mg in adults with overweight or obesity (OASIS 4). N Engl J Med 2025;393:1119-30. (2025)
8. StudyChun E et al. Weight loss and body composition after compounded semaglutide treatment in a real world setting. Diabetes Obes Metab 2025;27:1554-7. (2025)
9. StudyBelcourt J, Sapowadia A, White CM. Compounded semaglutide and tirzepatide products use unique formulations but efficacy and safety largely unknown. Ann Pharmacother 2026;60. (2026)
10. StudyMcCall KL et al. Safety analysis of compounded GLP-1 receptor agonists: a pharmacovigilance study using the FDA Adverse Event Reporting System. Expert Opin Drug Saf 2026;25. (2026)
11. StudyLambson JE et al. Administration errors of compounded semaglutide reported to a poison control center: case series. J Am Pharm Assoc 2023;63:1643-5. (2023)
12. LabelNovo Nordisk. Wegovy (semaglutide) injection and tablets: prescribing information, revised June 2026 (DailyMed setid ee06186f-2aa3-4990-a760-757579d8f77b). (2026)
13. LabelNovo Nordisk. Ozempic (semaglutide) injection: prescribing information, revised June 2026 (DailyMed setid adec4fd2-6858-4c99-91d4-531f5f2a2d79). (2026)
14. RegulatoryFDA. FDA's concerns with unapproved GLP-1 drugs used for weight loss (compounding after the shortages, salt forms, adverse event reports; content current as of October 1, 2026).
15. RegulatoryFDA. Declaratory order: resolution of shortages of semaglutide injection products (Ozempic and Wegovy), February 21, 2025. (2025)
16. RegulatoryFDA. FDA alerts health care providers, compounders and patients of dosing errors associated with compounded injectable semaglutide products. July 26, 2024 (examples as summarized by Patient Care Online, July 30, 2024). (2024)
17. NewsWalker B, Brophy RA. Ozempic shortages present risks and rewards for compounding pharmacies (FDA's April 27, 2023 letter to NABP and May 2023 statement on semaglutide salt forms). McGuireWoods client alert, July 20, 2023. (2023)
18. RegulatoryFDA. FDA warns 30 telehealth companies against illegal marketing of compounded GLP-1s. Press announcement, March 2026. (2026)
19. RegulatoryFederal Register. List of bulk drug substances for which there is a clinical need under section 503B: FDA proposes not to include semaglutide, tirzepatide and liraglutide. May 1, 2026. (2026)
20. NewsBuntz B. FDA logs more than 1,700 adverse event reports involving compounded semaglutide and tirzepatide (990 and 730 as of May 31, 2026). Drug Discovery and Development, August 24, 2026. (2026)